These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2154921)

  • 1. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Adcock L; Beecham J
    Am J Clin Oncol; 1990 Feb; 13(1):32-4. PubMed ID: 2154921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gynecologic Oncology Group experience with ifosfamide.
    Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):6-10. PubMed ID: 2159188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Beecham J; Homesley H; Yordan E
    J Clin Oncol; 1991 Nov; 9(11):1962-6. PubMed ID: 1941054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
    Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; DiSaia PJ; Christopherson WA
    Cancer Treat Rep; 1987 Jun; 71(6):661-2. PubMed ID: 3034423
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG; Blessing JA; Soper JT; Barter JF
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
    Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
    Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Gallup DG; Blessing JA; Andersen W; Morgan MA;
    Gynecol Oncol; 2003 Apr; 89(1):48-51. PubMed ID: 12694653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
    Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group).
    Muss HB; Bundy BN; Homesley HD; Wilbanks G
    Invest New Drugs; 1987; 5(2):199-202. PubMed ID: 3654152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
    Duska LR; Blessing JA; Rotmensch J; Mannel RS; Hanjani P; Rose PG; Dizon DS
    Gynecol Oncol; 2014 Oct; 135(1):44-8. PubMed ID: 25091619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group.
    Thigpen JT; Blessing JA; Wilbanks GD
    Am J Clin Oncol; 1986 Feb; 9(1):18-20. PubMed ID: 3953489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
    Smith HO; Blessing JA; Vaccarello L
    Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
    Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Barrett RJ; McGehee R
    Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
    Omura GA; Blessing JA; Major F; Lifshitz S; Ehrlich CE; Mangan C; Beecham J; Park R; Silverberg S
    J Clin Oncol; 1985 Sep; 3(9):1240-5. PubMed ID: 3897471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma.
    Boadle DJ; Tattersall MH
    Aust N Z J Obstet Gynaecol; 1987 Nov; 27(4):341-2. PubMed ID: 3453676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Kilgore LC; Mannel R; Van Le L
    Am J Clin Oncol; 2000 Aug; 23(4):355-7. PubMed ID: 10955863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.